KKR to invest in Precipart Group Ltd.
Kohlberg Kravis Roberts (KKR) has agreed to make a significant strategic investment in Precipart Group Ltd., a leading contract manufacturer of precision components for the medical device and aerospace industries. KKR plans to support the company in its continued growth organically and through M&A.
Precipart, founded in 1950 by the Laubscher family with roots in Swiss engineering and manufacturing, is a leading contract development and manufacturing organization of highly engineered precision components and assemblies, primarily for the medical device industry as well as the aerospace and industrial markets. Precipart, through its mission to Engineer Possible, is a comprehensive solution provider supporting its customers from the concept phase to serial production and in managing their growing supply chain complexity. Major product offerings include precision machining, micro mechanical components, assemblies, gear systems, motion solutions, technical ceramics and advanced 3D printing.
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people and supporting growth in its portfolio companies and communities. KKR is investing in Precipart through its Health Care Strategic Growth Fund, a fund dedicated to investing in high-growth healthcare-related companies to which KKR can be a unique strategic partner in helping reach scale.
The Laubscher family remains highly committed to Precipart and is retaining a significant minority ownership stake in the company.
Oaklins’ team in Switzerland acted as the exclusive sell-side advisor to the shareholders of Precipart in the transaction. Oaklins TM Capital approached potential investors in the US market and supported the transaction at its early stages.
Oliver Laubscher
Member of the Board and CEO, Precipart Group Ltd.
Talk to the deal team
Christoph Walker
Oaklins Switzerland
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreDolmans Landscaping Group has welcomed Foreman Capital as a new shareholder to support further growth
Dolmans Landscaping Group, a leading full-service provider of landscaping services, has welcomed Foreman Capital as a new shareholder. By partnering with Foreman Capital, which has extensive experience in building stronger companies in the maintenance of public spaces, Dolmans can accelerate its growth trajectory across core verticals and further professionalize the business.
Learn moreNuzoa has acquired Agrofauna
Nuzoa, a provider of value-added services for pets and livestock in the Iberian Peninsula, has acquired 100% of Agrofauna. This transaction reinforces Nuzoa’s presence in the Portuguese market, particularly in the northern region, marking another step toward its ambition to become the leading operator while further consolidating its brand across Iberia.
Learn more